155 related articles for article (PubMed ID: 26970151)
1. Discordance between patient and clinician reports of adverse reactions to MDR-TB treatment.
Kelly AM; Smith B; Luo Z; Given B; Wehrwein T; Master I; Farley JE
Int J Tuberc Lung Dis; 2016 Apr; 20(4):442-7. PubMed ID: 26970151
[TBL] [Abstract][Full Text] [Related]
2. Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care.
Brust JC; Shah NS; Scott M; Chaiyachati K; Lygizos M; van der Merwe TL; Bamber S; Radebe Z; Loveday M; Moll AP; Margot B; Lalloo UG; Friedland GH; Gandhi NR
Int J Tuberc Lung Dis; 2012 Aug; 16(8):998-1004. PubMed ID: 22668560
[TBL] [Abstract][Full Text] [Related]
3. Serious treatment related adverse drug reactions amongst anti-retroviral naïve MDR-TB patients.
Van der Walt M; Lancaster J; Odendaal R; Davis JG; Shean K; Farley J
PLoS One; 2013; 8(4):e58817. PubMed ID: 23573193
[TBL] [Abstract][Full Text] [Related]
4. Low treatment initiation rates among multidrug-resistant tuberculosis patients in Gauteng, South Africa, 2011.
Ebonwu JI; Tint KS; Ihekweazu C
Int J Tuberc Lung Dis; 2013 Aug; 17(8):1043-8. PubMed ID: 23827028
[TBL] [Abstract][Full Text] [Related]
5. Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients.
Ahmad N; Javaid A; Syed Sulaiman SA; Afridi AK; Zainab ; Khan AH
Am J Ther; 2018; 25(5):e533-e540. PubMed ID: 26938643
[TBL] [Abstract][Full Text] [Related]
6. Converging risk factors but no association between HIV infection and multidrug-resistant tuberculosis in Kazakhstan.
van den Hof S; Tursynbayeva A; Abildaev T; Adenov M; Pak S; Bekembayeva G; Ismailov S
Int J Tuberc Lung Dis; 2013 Apr; 17(4):526-31. PubMed ID: 23485387
[TBL] [Abstract][Full Text] [Related]
7. Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa.
Schnippel K; Firnhaber C; Berhanu R; Page-Shipp L; Sinanovic E
Int J Tuberc Lung Dis; 2018 Apr; 22(4):393-398. PubMed ID: 29562986
[TBL] [Abstract][Full Text] [Related]
8. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003.
Brust JC; Gandhi NR; Carrara H; Osburn G; Padayatchi N
Int J Tuberc Lung Dis; 2010 Apr; 14(4):413-9. PubMed ID: 20202298
[TBL] [Abstract][Full Text] [Related]
9. Statistical factors associated with utilisation of ototoxicity monitoring services for multi-drug-resistant tuberculosis patients in the Western Cape.
Ramma L; Nhokwara PT; Rogers C
S Afr J Commun Disord; 2019 Jan; 66(1):e1-e6. PubMed ID: 30843411
[TBL] [Abstract][Full Text] [Related]
10. Predictors of cure among HIV co-infected multidrug-resistant TB patients at Sizwe Tropical Disease Hospital Johannesburg, South Africa.
Umanah TA; Ncayiyana JR; Nyasulu PS
Trans R Soc Trop Med Hyg; 2015 May; 109(5):340-8. PubMed ID: 25787727
[TBL] [Abstract][Full Text] [Related]
11. Drug-resistant tuberculosis in HIV-infected patients in a national referral hospital, Phnom Penh, Cambodia.
Walls G; Bulifon S; Breysse S; Daneth T; Bonnet M; Hurtado N; Molfino L
Glob Health Action; 2015; 8():25964. PubMed ID: 25623609
[TBL] [Abstract][Full Text] [Related]
12. Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort.
Sagwa EL; Ruswa N; Mavhunga F; Rennie T; Leufkens HG; Mantel-Teeuwisse AK
BMC Pharmacol Toxicol; 2015 Dec; 16():36. PubMed ID: 26654443
[TBL] [Abstract][Full Text] [Related]
13. Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa.
Cox H; Hughes J; Daniels J; Azevedo V; McDermid C; Poolman M; Boulle A; Goemaere E; van Cutsem G
Int J Tuberc Lung Dis; 2014 Apr; 18(4):441-8. PubMed ID: 24670700
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Concurrent Antiretroviral Therapy and MDR-TB Treatment on Adverse Events.
Smith JP; Gandhi NR; Shah NS; Mlisana K; Moodley P; Johnson BA; Allana S; Campbell A; Nelson KN; Master I; Brust JCM
J Acquir Immune Defic Syndr; 2020 Jan; 83(1):47-55. PubMed ID: 31809360
[TBL] [Abstract][Full Text] [Related]
15. Community-based care vs. centralised hospitalisation for MDR-TB patients, KwaZulu-Natal, South Africa.
Loveday M; Wallengren K; Brust J; Roberts J; Voce A; Margot B; Ngozo J; Master I; Cassell G; Padayatchi N
Int J Tuberc Lung Dis; 2015 Feb; 19(2):163-71. PubMed ID: 25574914
[TBL] [Abstract][Full Text] [Related]
16. Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.
Rupani MP; Dave JD; Parmar VB; Singh MP; Parikh KD
Natl Med J India; 2020; 33(1):10-14. PubMed ID: 33565479
[TBL] [Abstract][Full Text] [Related]
17. The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa.
Sineke T; Evans D; Schnippel K; van Aswegen H; Berhanu R; Musakwa N; Lönnmark E; Long L; Rosen S
Health Qual Life Outcomes; 2019 May; 17(1):94. PubMed ID: 31151398
[TBL] [Abstract][Full Text] [Related]
18. Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection.
Hong H; Budhathoki C; Farley JE
Int J Tuberc Lung Dis; 2018 Jun; 22(6):667-674. PubMed ID: 29862952
[TBL] [Abstract][Full Text] [Related]
19. Peripheral neuropathy associated with treatment for multidrug-resistant tuberculosis.
Shin SS; Hyson AM; Castañeda C; Sánchez E; Alcántara F; Mitnick CD; Fawzi MC; Bayona J; Farmer PE; Kim JY; Furin JJ
Int J Tuberc Lung Dis; 2003 Apr; 7(4):347-53. PubMed ID: 12729340
[TBL] [Abstract][Full Text] [Related]
20. Risk factors and outcome of human immunodeficiency virus-infected patients with sporadic multidrug-resistant tuberculosis in New York City.
Mannheimer SB; Sepkowitz KA; Stoeckle M; Friedman CR; Hafner A; Riley LW
Int J Tuberc Lung Dis; 1997 Aug; 1(4):319-25. PubMed ID: 9432387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
